Medtronic Initiates Landmark U.S. Drug-Eluting Balloon Study

Expanding its commitment to developing innovative treatments for cardiovascular disease and the evidence to support their adoption, Medtronic announced the start of the Medtronic IN.PACT SFA II study, the company’s first U.S. clinical trial for its line of IN.PACT drug-eluting balloons.
MarketWatch